ACELYRIN, Inc. financial data

Symbol
SLRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
4149 Liberty Canyon Rd., Agoura Hills, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 882 % -41.1%
Debt-to-equity 13.1 % -3.11%
Return On Equity -44.1 % +53.6%
Return On Assets -39 % +28.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 100M shares +3.07%
Common Stock, Shares, Outstanding 99.9M shares +3512%
Entity Public Float 1.46B USD
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 99.8M shares +3.06%
Weighted Average Number of Shares Outstanding, Diluted 99.8M shares +3.06%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 249M USD -14%
General and Administrative Expense 75.4M USD +51.4%
Operating Income (Loss) -336M USD +1.21%
Net Income (Loss) Attributable to Parent -264M USD +13.7%
Earnings Per Share, Basic 2.74 USD/shares +43.7%
Earnings Per Share, Diluted 2.74 USD/shares +43.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 216M USD -43.3%
Cash, Cash Equivalents, and Short-term Investments 563M USD -28.6%
Assets, Current 597M USD -24.9%
Property, Plant and Equipment, Net 1.7M USD -20.2%
Operating Lease, Right-of-Use Asset 6.98M USD +463%
Assets 618M USD -22.8%
Accounts Payable, Current 17.6M USD -6.16%
Liabilities, Current 83.5M USD +24.8%
Operating Lease, Liability, Noncurrent 6.56M USD +424%
Liabilities 90M USD +32.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 384K USD
Retained Earnings (Accumulated Deficit) -658M USD -67.2%
Stockholders' Equity Attributable to Parent 528M USD -27.9%
Liabilities and Equity 618M USD -22.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -57.3M USD -126%
Net Cash Provided by (Used in) Financing Activities 2.81M USD
Net Cash Provided by (Used in) Investing Activities 101M USD +112%
Common Stock, Shares Authorized 790M shares 0%
Common Stock, Shares, Issued 99.9M shares +2.78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 46.4M USD +110%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 217M USD -43.2%
Deferred Tax Assets, Valuation Allowance 98.7M USD +316%
Deferred Tax Assets, Gross 99M USD +317%
Operating Lease, Liability 7.38M USD +415%
Payments to Acquire Property, Plant, and Equipment 55K USD -76.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -264M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid 11.1M USD +479%
Property, Plant and Equipment, Gross 2.03M USD -7.47%
Operating Lease, Liability, Current 824K USD +355%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.28M USD +489%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.2M USD +487%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.68M USD +673%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.35M USD +491%
Deferred Tax Assets, Operating Loss Carryforwards 19.6M USD +217%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 2.35M USD +355%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.29M USD +460%
Additional Paid in Capital 1.19B USD +5.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 55K USD
Deferred Tax Assets, Net of Valuation Allowance 252K USD
Share-based Payment Arrangement, Expense 53.8M USD +65.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares